2024-01-20 18:43:00
The National Agency for the Safety of Medicines and Health Products (ANSM) reported the January 18, 2024 a stock shortage concerns the vaccine Avaxim 160 U (Laboratory: Sanofi Pasteur).
The whole inactivated vaccine Avaxim 160 U is indicated for active immunization once morest infection caused by the hepatitis A virus in adolescents from the age of 16 and in adults. This vaccine should be administered in accordance with official recommendations.
- The stock shortage concerns city pharmacies.
- Distribution is normal in the hospital.
- The normal delivery date is planned for the end of February 2024
In a vaccination schedule started with Avaxim 160 U, Havrix 1440 U vaccine can be used as a second dose. The Vaqta 50 U vaccine can also be used from the age of 18.
In order to secure the situation in France as much as possible and to preserve available stocks, the sale and export of the medicine by wholesale distributors abroad is prohibited from the publication of this information sheet on the website of the National Agency for the Safety of Medicines and Health Products (ANSM), in application of public health law 2016-41 published in the Official Journal on January 27, 2016 and the provisions of articles L.5121-30 and L.5124 -17-3 of the Public Health Code. This measure prohibiting sales outside the national territory, or to wholesale distributors for export, must be applied and respected until the medicine is made available normally, allowing a continuous and appropriate supply to the national market.
Source: National Agency for Medicines and Health Products (ANSM).
1705803248
#stock #Avaxim #vaccine #pharmacies..
